Low dose aspirin increases 15-epi-lipoxin A4 levels in diabetic chronic kidney disease patients

Abstract Background Resolution of inflammation is regulated by endogenous lipid mediators, such as lipoxins and their epimers, including 15-epi-lipoxin A4 (15-epi-LXA4). However, there is no information on 15-epi-LXA4 and its in vivo regulation in chronic kidney disease (CKD) patients. Study design Open label randomized clinical trial. Setting and participants 50 participants with chronic kidney disease (CKD) stage 3 and 4 without prior cardiovascular disease (25 in the aspirin group and 25 in the standard group) followed for 46 months. Intervention Aspirin (100 mg/day) or standard treatment. Aim To analyze the effect of aspirin on plasma 15-epi-LXA4 levels and inflammatory markers in CKD patients. Results Baseline plasma15-epi-LXA4 levels were lower in diabetic (1.22 ± 0.99 ng/ml) than in non-diabetic CKD patients (2.05 ± 1.06 ng/ml, p Conclusions Diabetic patients with CKD have lower circulating 15-epi-LXA4 levels than non-diabetic CKD patients. Low dose aspirin for 12 months increased 15-epi-LXA4 levels in diabetic patients. Given its anti-inflammatory properties, this increase in 15-epi-LXA4 levels may contribute to the beneficial effects of low dose aspirin.